RIGEN-BIO

Shanghai Rigen Biotechnology Co., Ltd. (referred to as "RIGEN-BIO") was founded in 2017. The company is committed to serving the entire process of preoperative auxiliary diagnosis, postoperative recurrence monitoring, and comprehensive clinical management for thyroid cancer, optimizing medical resources, and benefiting more patients. Based on clinical needs and independent innovation, RIGEN-BIO focuses on thyroid nodules/thyroid cancer. It has developed a full range of products covering the entire process, including disposable thyroid biopsy needles, multi-gene qPCR detection kits, NGS detection kits, Thyroscan® thyroid nodule benign-malignant classifier, and postoperative recurrence monitoring. These aim to provide customers with an overall solution for molecular diagnostic products for benign-malignant judgment and recurrence monitoring of thyroid cancer, comprehensive management products for the whole process, and surgical consumables. The company's products have been serving nearly a hundred large tertiary general hospitals and cancer specialty hospitals across more than fifteen provinces/municipalities in China.